RAD001 can reverse drug resistance of SGC7901/DDP cells

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 9171-9177

  Ying, Liu ^a   Zu an, Zhu ^a   Qing hua, Liu ^a   Qing yan, Kong ^a   Lei, Liu ^a   Tao, Cui ^a   Yong ping, Wu ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; mTOR; RAD001; SGC7901 DDP

Indexed keywords

CISPLATIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; RAPAMYCIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL LEVEL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG SENSITIVITY; FLOW CYTOMETRY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MTT ASSAY; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; IC50; METABOLISM; PATHOLOGY; STOMACH TUMOR; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; INHIBITORY CONCENTRATION 50; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; SIROLIMUS; STOMACH NEOPLASMS; TIME FACTORS;

EID: 84919839448     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-1719-1     Document Type: Article

References (23)

1. Alcantara LM, Kim J, Moraes CB, Franco CH, Franzoi KD, Lee S, et al. Chemosensitization potential of P-glycoprotein inhibitors in malaria parasites. Exp Parasitol. 2013;134:235–43.
2. Luo L, Sun YJ, Yang L, Huang S, Wu YJ. Avermectin induces P-glycoprotein expression in S2 cells via the calcium/calmodulin/NF-κB pathway. Chem Biol Interact. 2013;203:430–9.
3. Sedláková I, Laco J, Tošner J, Caltová K, Cervinka M, Rezáč A, et al. Proteins of resistance and drug resistance in ovarian carcinoma patients. Klin Onkol. 2012;25:457–63.
4. Melguizo C, Prados J, Luque R, Ortiz R, Rama AR, Caba O, et al. Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance. Cancer Chemother Pharmacol. 2013;71:537–41.
5. Munkácsy G, Abdul-Ghani R, Mihály Z, Tegze B, Tchernitsa O, Surowiak P, et al. PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer. Br J Cancer. 2010;102:361–3688.
6. Doroshow JH. Prevention of doxorubicin-induced killing of MCF-7 human-breast cancer-cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun. 1986;135:330–5.
7. Lage H, Helmbach H, Dietel M, Schadendorf D. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer. 2000;82:488–91.
8. Kuang Y, Cai J, Li D, Han Q, Cao J, Wang Z. Repression of dicer is associated with invasive phenotype and chemoresistance in ovarian cancer. Oncol Lett. 2013;5:1149–54.
9. Shen Y, Ren ML, Shi YH, Zhang YX, Cai YL. Octreotide is the favorable alternative for cisplatin resistance reversal of ovarian cancer in vitro and in nude mice in vivo. Eur J Gynaecol Oncol. 2012;33:584–90.
10. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–79.
11. Johnsson A, Zeelenberg I, Min Y, Hilinski J, Berry C, Howell SB, et al. Identification of genes differentially expressed in association with acquired cisplatin resistance. Br J Cancer. 2000;83:1047–54.
12. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27:2278–87.
13. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004;91:1420–4.
14. Mayer I. Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. Clin Adv Hematol Oncol. 2013;11(4):217–24.
15. Morgensztern D, McLeod HL. PI3k/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16(8):797–803.
16. Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li JH, et al. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer. 2008;122(2):433–43.
17. Zhang W, Ling V. Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells. J Cell Physiol. 2000;184(1):17–26.
18. Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood. 1992;80(6):1528–36.
19. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92(16):1295–302.
20. Hoof T, Demmer A, Christians U, Tümmler B. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin. Eur J Pharmacol. 1993;246(1):53–8.
21. Colnaghi R, Connell CM, Barrett RM, Wheatley SP. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem. 2006;281(44):33450–6.
22. Wolanin K, Piwocka K. Role of survivin in mitosis. Postepy Biochem. 2007;53(1):10–8.
23. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer. 2005;8(2):86–94.